TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19620898

Group type: EXPERIMENTAL
Intervention: No warm-up (NWU)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Steady state warm-up
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Interval warm-up
Number of subjects: 11
Study: 18198305

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR, 25% restriction)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calorie restriction plus structured exercise (CR+EX, 12.5% restriction plus 12.5% increased energy expenditure via exercise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD, 890 kcal/d supplement diet until 15% weight loss, then weight maintenance)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (weight maintenance)
Number of subjects: 48
Study: 15925776

Group type: EXPERIMENTAL
Intervention: Blind transpyloric placement using a specifically designed nasojejunal tube (NJT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard nasogastric tube (NGT)
Number of subjects: 14
Study: 12011906

Group type: EXPERIMENTAL
Intervention: 30-degree head-up position with 10-degree leg elevation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine for 10 minutes without leg elevation alternating with 10 minutes of side-lying
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supine for 10 minutes with leg elevation at 10 degrees alternating with side-lying every 10 minutes
Number of subjects: 10
Study: 9657627

Group type: EXPERIMENTAL
Intervention: Derapril
Number of subjects: 37

Group type: COMPARATOR
Intervention: Manidipine
Number of subjects: 37
Study: 7664860

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled bumetanide (2 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral placebo + inhaled frusemide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral flurbiprofen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral flurbiprofen alone
Number of subjects: 14
Study: 2651176

Group type: EXPERIMENTAL
Intervention: Bacampicillin suspension, given twice daily, 40 mg/kg body weight for 10 days
Number of subjects: 97

Group type: COMPARATOR
Intervention: Amoxycillin suspension, given three times daily, 40 mg/kg body weight for 10 days
Number of subjects: 97
Study: 137987

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 126
Study: 30883562

Group type: EXPERIMENTAL
Intervention: Park upkeep, presence of playground or outdoor fitness equipment
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Presence of sport field (soccer and basketball)
Number of subjects: 972
Study: 28494884

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope-guided intubation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Macintosh laryngoscope-guided intubation
Number of subjects: 74
Study: 27872119

Group type: EXPERIMENTAL
Intervention: Intravenous administration of nicorandil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous administration of adenosine
Number of subjects: 50
Study: 24708195

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study: 22723612

Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230
Study: 20197236

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17403493

Group type: EXPERIMENTAL
Intervention: Culturally rooted, couple-focused HIV prevention program
Number of subjects: 0
Study: 17050270

Group type: EXPERIMENTAL
Intervention: Right temporal resections (n=15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Left temporal resections (n=13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control participants (n=15)
Number of subjects: 43
Study: 12891310

Group type: EXPERIMENTAL
Intervention: Ramipril (starting dose 2.5 mg in group 1 and 5 mg in group 2, increased to 10 mg daily over 8 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ramipril (group 1: gradual regimen starting at 2.5 mg; group 2: more active regimen starting at 5 mg)
Number of subjects: 30
Study: 10472219

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg kg‐1 i.v.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 8735088

Group type: EXPERIMENTAL
Intervention: AMPLICOR C. trachomatis Test (urine specimens)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Endocervical swab specimen culture
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: AMPLICOR C. trachomatis Test (endocervical swab specimens)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Urine PCR
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Culture of urethral specimens
Number of subjects: 1238
Study: 1670442

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with no immediate injection of enoxaparin (Group I, 65 patients)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 20 mg of enoxaparin one hour after the onset of anaesthesia (Group II, 61 patients)
Number of subjects: 188

Group type: COMPARATOR
Intervention: General anaesthesia with 40 mg of enoxaparin 12 hours prior to surgery (Group III, 62 patients)
Number of subjects: 188
Study: 6405346

Group type: EXPERIMENTAL
Intervention: Carbogen inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous infusion of papaverine and low‐molecular dextran
Number of subjects: 0
Study: 31468208

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 24
Study: 28319467

Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 26353833

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo + Methotrexate (MTX)
Number of subjects: 619
Study: 23446330

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (MicroHip)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Transgluteal approach
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both approaches (MicroHip and Transgluteal)
Number of subjects: 134
Study: 22321673

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 19966482

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain HSK201
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (non-fermented milk)
Number of subjects: 19
Study: 17624838

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 0
Study: 14767020

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (GTN)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (salbutamol)
Number of subjects: 41
Study: 11991909

Group type: EXPERIMENTAL
Intervention: Behavioural infant sleep intervention (controlled crying)
Number of subjects: 156
Study: 9602870

Group type: EXPERIMENTAL
Intervention: Combination of calcipotriol and betamethasone valerate after 2 weeks of calcipotriol monotherapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Calcipotriol monotherapy
Number of subjects: 169
Study: 7997001

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Day-care treatment
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: At-home treatment after one week of day-care
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 437
Study: 2574675

Group type: EXPERIMENTAL
Intervention: Ramixotidine 750 mg p.o. administered at 22.00 h
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 4370512

Group type: EXPERIMENTAL
Intervention: Tone pips at 250 Hz
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tone pips at 1000 Hz
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tone pips at 4000 Hz
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Wide band clicks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition (no acoustic stimuli)
Number of subjects: 2
Study: 30523659

Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining exergaming and physical therapy, 90 minutes twice a week for 12 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining exergaming and physical therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (only assessment)
Number of subjects: 17
Study: 28396048

Group type: EXPERIMENTAL
Intervention: S4 (aroma + taste)
Number of subjects: 26

Group type: COMPARATOR
Intervention: S1 (water)
Number of subjects: 26
Study: 26189039

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305
Study: 23614897

Group type: EXPERIMENTAL
Intervention: FM containing 10(7) cfu LG2055/g
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: FM containing 10(6) cfu LG2055/g
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (0 cfu LG2055/g)
Number of subjects: 210
Study: 21889800

Group type: EXPERIMENTAL
Intervention: Educational intervention (lecture, video, and classroom demonstration) promoting spectacle purchase at intervention schools.
Number of subjects: 15404

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 15404
Study: 20218087

Group type: EXPERIMENTAL
Intervention: MLD (60 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MLD (30 min) + IPC (30 min)
Number of subjects: 27
Study: 17112403

Group type: EXPERIMENTAL
Intervention: 10000 lux light treatment and a placebo capsule
Number of subjects: 96

Group type: COMPARATOR
Intervention: 100 lux light treatment (placebo light) and 20 mg fluoxetine
Number of subjects: 96
Study: 14670810

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally 4 times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lean controls (historical control group)
Number of subjects: 10
Study: 11578293

Group type: EXPERIMENTAL
Intervention: Intravenous crystalloid based on body-weight (group 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No intravenous fluid (group 1)
Number of subjects: 41
Study: 9631992

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluconazole 450 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 8073312

Group type: EXPERIMENTAL
Intervention: Group education intervention for chronic back pain
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Group education intervention for acute back pain (including work-site visits)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Group education intervention (various studies)
Number of subjects: 13
Study: 2146875

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (2 g/kg/month)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 49
Study: 56589

Group type: EXPERIMENTAL
Intervention: Somatostatin (growth-hormone release-inhibiting hormone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 0
Study: 31169572

Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 140
Study: 28157691

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alfacalcidiol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined alfacalcidiol and metformin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vitamin D therapy
Number of subjects: 39
Study: 25921346

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) using various ablation technologies (duty-cycled phased RF multipolar ablation with PVAC, cooled-tip RF ablation, cryoballoon ablation)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Phased RF (PVAC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Irrigated RF
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 52
Study: 24118062

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/day)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study: 21329776

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination (2 μg/dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) vaccination (10 μg/dose)
Number of subjects: 80
Study: 19192457

Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of lithium and divalproex
Number of subjects: 31
Study: 17339642

Group type: COMPARATOR
Intervention: Normal psychomotor activity
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Hypoactive psychomotor activity
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Hyperactive psychomotor activity
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Mixed psychomotor activity
Number of subjects: 457
Study: 15754692

Group type: EXPERIMENTAL
Intervention: Lobe-isthmusectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 80
Study: 11101487

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (20 g powder/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8832535

Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone (DEX)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone (HCO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study: 1561270

Group type: EXPERIMENTAL
Intervention: Autologous fibrin adhesive used to seal split-thickness skin grafts
Number of subjects: 7

Group type: COMPARATOR
Intervention: No adhesive used (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both sealed and unsealed grafts
Number of subjects: 7
Study: 6321455

Group type: EXPERIMENTAL
Intervention: Doxepin (188 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desipramine (173 mg/day)
Number of subjects: 36
Study: 30357468

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 131
Study: 30572837

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg tramadol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1 mg/kg tramadol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study: 26811430

Group type: EXPERIMENTAL
Intervention: artesunate + sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 0
Study: 24931567

Group type: EXPERIMENTAL
Intervention: MSDC-0160 (150 mg once daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 22818063

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg (T20 mg)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg (T40 mg)
Number of subjects: 357
Study: 19439084

Group type: EXPERIMENTAL
Intervention: RTW‐E programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 200
Study: 17311545

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no GH replacement therapy)
Number of subjects: 20
Study: 15140122

Group type: EXPERIMENTAL
Intervention: Extensive screening for occult cancer
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no further testing)
Number of subjects: 201
Study: 11782331

Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl (1 microg/mL) combined with Lidocaine 0.4% (F-L Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural Morphine (20 microg/kg bolus every eight hours) (M Group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl with Lidocaine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural Morphine
Number of subjects: 30
Study: 10354692

Group type: EXPERIMENTAL
Intervention: Exposure to copper (mean concentration below 0.05 mg x m‐3)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (not exposed to copper)
Number of subjects: 267
Study: 8131523

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methacholine inhalation challenge (MIC)
Number of subjects: 16
Study: 2632113

Group type: EXPERIMENTAL
Intervention: Anti-erythrocyte aggregation (troxerutin)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (matched for age, sex, risk factors, and vascular disease)
Number of subjects: 64
Study: 1194144

Group type: EXPERIMENTAL
Intervention: Inspiratory elastic load (12.1 cmH2O/l)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No inspiratory elastic load (control)
Number of subjects: 7
Study: 31363878

Group type: EXPERIMENTAL
Intervention: CCTA with iodixanol (270 mg I/mL), scanned with 100 kV, reconstruction by AIDR
Number of subjects: 68

Group type: COMPARATOR
Intervention: CCTA with iopromide (370 mg I/mL), scanned with 120 kV, reconstruction by filtered back projection
Number of subjects: 68
Study: 28524027

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 68
Study: 25374039

Group type: EXPERIMENTAL
Intervention: Gender-bias-habit-changing intervention (2.5-hour workshop)
Number of subjects: 92
Study: 24101053

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib in MET-positive patients (n = 66)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib in MET-negative patients (n = 62)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control (placebo plus erlotinib) in MET-positive patients (n = 62)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib
Number of subjects: 137
Study: 21938606

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19285163

Group type: EXPERIMENTAL
Intervention: Noncontrast head computed tomography (CT) scan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain specific serum biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncontrast head CT scan with normal neurologic evaluation
Number of subjects: 0
Study: 16956484

Group type: EXPERIMENTAL
Intervention: Conventional emergency surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 0
Study: 15228830

Group type: EXPERIMENTAL
Intervention: Somatostatin analogue (Sandostatin 300 microgram subcutaneously/day in three divided doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional methods (nil per orum, total parenteral nutrition, antibiotics, skin and wound care, control of sepsis)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Somatostatin analogue
Number of subjects: 33
Study: 11097669

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1 mg morphine
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with 50 microg fentanyl
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with 10 microg sufentanil
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone
Number of subjects: 39
Study: 9411596

Group type: EXPERIMENTAL
Intervention: Babyhaler with a face mask
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aeroscopic
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Other spacer devices (Aerochamber, Nebuhaler, Volumatic)
Number of subjects: 100
Study: 8477148

Group type: EXPERIMENTAL
Intervention: l-alpha-glyceryl-phosphorylcholine (alpha GPC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: ST200 (acetyl-l-carnitine)
Number of subjects: 126
Study: 2948256

Group type: EXPERIMENTAL
Intervention: Pindolol (2.5-7.5 mg, administered gradually by mouth)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms by dosimetric aerosol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms by dosimetric aerosol)
Number of subjects: 17
Study: 30322633

Group type: EXPERIMENTAL
Intervention: In-cabin intubation protocol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard outdoor intubation
Number of subjects: 14
Study: 27524393

Group type: EXPERIMENTAL
Intervention: Treadmill training plus VR
Number of subjects: 302

Group type: COMPARATOR
Intervention: Treadmill training alone
Number of subjects: 302

Group type: COMPARATOR
Intervention: Comparison of both groups after training
Number of subjects: 302
Study: 25977176

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) and breast physical examination (BPx)
Number of subjects: 12660

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12660
Study: 23458938

Group type: EXPERIMENTAL
Intervention: No. 14 pediatric Foley catheter/balloon for 5 days (n=13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No balloon (n=15)
Number of subjects: 28
Study: 20377770

Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fe chloride
Number of subjects: 108
Study: 18197911

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in pleural fluid for CHF patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NT-proBNP level >or=2220 pg/mL
Number of subjects: 40
Study: 17163250

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20mg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Candesartan cilexetil 8mg
Number of subjects: 635
Study: 14583239

Group type: EXPERIMENTAL
Intervention: Aerobic training program (8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wait-control group
Number of subjects: 28